Seroatlas · Human Serome Atlas

VASH2

Tubulinyl-Tyr carboxypeptidase 2

Also known as: FLJ12505, VASH2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86V25
Gene: VASH2
Ensembl: ENSG00000143494
Chromosome: 1
Canonical length: 355 aa
Protein class: Enzymes, Predicted intracellular proteins, Predicted secreted proteins
Subcellular location: Cytosol
Secretome location: Secreted to blood

OverviewNCBI Gene

Enables actin binding activity; metallocarboxypeptidase activity; and microtubule binding activity. Involved in axon development and proteolysis. Acts upstream of or within cell-cell fusion; positive regulation of angiogenesis; and positive regulation of endothelial cell proliferation. Located in cytosol. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

355 residues, UniProt reviewed canonical sequence.

>Q86V25|VASH2
     1  MTGSAADTHR CPHPKGAKGT RSRSSHARPV SLATSGGSEE EDKDGGVLFH VNKSGFPIDS
    61  HTWERMWMHV AKVHPKGGEM VGAIRNAAFL AKPSIPQVPN YRLSMTIPDW LQAIQNYMKT
   121  LQYNHTGTQF FEIRKMRPLS GLMETAKEMT RESLPIKCLE AVILGIYLTN GQPSIERFPI
   181  SFKTYFSGNY FHHVVLGIYC NGRYGSLGMS RRAELMDKPL TFRTLSDLIF DFEDSYKKYL
   241  HTVKKVKIGL YVPHEPHSFQ PIEWKQLVLN VSKMLRADIR KELEKYARDM RMKILKPASA
   301  HSPTQVRSRG KSLSPRRRQA SPPRRLGRRE KSPALPEKKV ADLSTLNEVG YQIRI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against VASH2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.39
Highest tissue expression: 6.8 nTPM

Expression across tissuesHPA

Tissue

testis: 6.8 nTPM
thymus: 4 nTPM
esophagus: 3.8 nTPM
appendix: 3.1 nTPM
prostate: 2.5 nTPM
gallbladder: 2.4 nTPM

Single-cell type

late spermatids: 179 nCPM
gonadotrophs: 160 nCPM
early spermatids: 137 nCPM
late primary spermatocytes: 66 nCPM
pdcs: 65 nCPM
fibro-adipogenic progenitors: 25 nCPM

Immune cell

plasmacytoid DC: 0.7 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

thalamus: 6 nTPM
pons: 5.2 nTPM
cerebral cortex: 4.2 nTPM
midbrain: 3.9 nTPM
amygdala: 3.8 nTPM
medulla oblongata: 3.8 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.66
gnomAD pLI: 0.24
gnomAD missense Z: 0.75
DepMap mean gene effect: 0.09
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of VASH2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

SVBP

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads VASH2 as an antibody target. Whether an autoantibody or antibody against VASH2 could matter depends on whether native VASH2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

VASH2 is annotated as secreted, so native VASH2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label VASH2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...